Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2022 - 2025)

Zentalis Pharmaceuticals has reported Cash from Operations over the past 4 years, most recently at 30940000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 30940000.0 for Q4 2025, up 22.07% from a year ago — trailing twelve months through Dec 2025 was 125247000.0 (up 26.7% YoY), and the annual figure for FY2025 was 125247000.0, up 26.7%.
  • Cash from Operations for Q4 2025 was 30940000.0 at Zentalis Pharmaceuticals, down from 26963000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ZNTL hit a ceiling of 26963000.0 in Q3 2025 and a floor of 79275000.0 in Q2 2023.
  • Median Cash from Operations over the past 4 years was 39183500.0 (2023), compared with a mean of 41730000.0.
  • Biggest five-year swings in Cash from Operations: crashed 84.24% in 2023 and later surged 55.67% in 2024.
  • Zentalis Pharmaceuticals' Cash from Operations stood at 37329000.0 in 2022, then dropped by 8.76% to 40599000.0 in 2023, then grew by 2.21% to 39702000.0 in 2024, then increased by 22.07% to 30940000.0 in 2025.
  • The last three reported values for Cash from Operations were 30940000.0 (Q4 2025), 26963000.0 (Q3 2025), and 34708000.0 (Q2 2025) per Business Quant data.